Experts has a new look! Let us know what you think of the updates.

Provide feedback
Home
Scholarly Works
Phase II study of CGP 69846A (ISIS 5132) in...
Journal article

Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: an NCIC clinical trials group study (NCIC IND.116)☆

Abstract

OBJECTIVE: ISIS 5132 is a 20-base phosphorothioate DNA oligonucleotide against human c-raf kinase, a downstream effector of ras oncogene function. C-raf kinase is a molecule in the MAP kinase signaling cascade which is essential for cellular proliferation, the overexpression of which leads to malignant expression. Activity of this compound was documented in a woman with ovarian cancer in a Phase I study. METHODS: We evaluated ISIS 5132 at a …

Authors

Oza AM; Elit L; Swenerton K; Faught W; Ghatage P; Carey M; McIntosh L; Dorr A; Holmlund JT; Eisenhauer E

Journal

Gynecologic Oncology, Vol. 89, No. 1, pp. 129–133

Publisher

Elsevier

Publication Date

April 2003

DOI

10.1016/s0090-8258(02)00144-0

ISSN

0090-8258